Drugs / Bifidobacterium longum BB536
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06044376 | May → Nov 2023 | — | Gadjah Mada University | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02566876 Comparator | Dec 2013 → Jul 2015 | dyspepsia, irritable bowel syndrome | Federico II University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bifidobacterium longum BB536 | “Formula milk with triple Bifidobacterium strain containing Bifidobacterium longum BB536 (6.9 x 10\^7 CFU/serving), Bifidobacterium breve M16-V (6.9 x 10\^7 CFU/serving),...” NCT06044376 ↗1“3 billions of Bifidobacterium longum BB536®, 1 billion of Bifidobacterium infantis M-63®, and 1 billion of Bifidobacterium breve M-16V®” NCT02566876 ↗ |
| Modality | Other / unclassified | “probiotic mixture of Bifidobacterium infantis M-63, breve M-16V, and longum BB536” PMID 27306945 ↗ Jan 2017 |
| Route | Oral | “oral administration of a mixture of Bifidobacteria” NCT02566876 ↗ |